| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01158937 | Cystic Fibrosis Pulmonary Exacerbation | Drug: Meropenem Infusion | St. Michael's Hospital, Toronto|Sunnybrook Health Sciences Centre|University of Toronto | | 2010-05-01 | 2015-05-20 |
| NCT01554124 | Meningitis | Drug: Meropenem | PENTA Foundation|Chiesi Farmaceutici S.p.A. | Phase 1|Phase 2 | 2013-02-01 | 2015-02-12 |
| NCT01429259 | Cystic Fibrosis|Pneumonia|Pseudomonas Aeruginosa Infection | Drug: meropenem | Joseph Kuti|Thrasher Research Fund|Hartford Hospital | Phase 4 | 2012-02-01 | 2015-03-26 |
| NCT00621192 | Necrotizing Enterocolitis|Intra-abdominal Infection | Drug: meropenem | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation | Phase 1|Phase 2 | 2008-06-01 | 2015-03-30 |
| NCT02506686 | Central Nervous System Infections | Drug: Meropenem | Huashan Hospital | Phase 4 | 2008-09-01 | 2015-07-21 |
| NCT01944319 | Lower Respiratory Tract Infection | Drug: Routine meropenem therapy|Drug: Meropenem therapy based on a PPK and PD model | Qingtao Zhou|Peking University Third Hospital | Phase 4 | 2013-07-01 | 2016-01-28 |
| NCT02615041 | Ventilator-Associated Pneumonia | Drug: Meropenem|Drug: Meropenem|Drug: Meropenem | Sutep Jaruratanasirikul|Prince of Songkla University | Phase 4 | 2004-01-01 | 2015-11-24 |
| NCT02437045 | Bloodstream Infections | Drug: Meropenem|Drug: Piperacillin-tazobactam combination product | The University of Queensland | Phase 4 | 2015-04-01 | 2016-11-13 |
| NCT00891423 | Sepsis | Drug: Meropenem short infusion|Drug: Meropenem extended infusion | Austin Health | | 2009-04-01 | 2015-07-30 |
| NCT02213796 | Initial Phase of Severe Sepsis and Septic Shock | Drug: Meropenem | Sutep Jaruratanasirikul|Prince of Songkla University | Phase 4 | 2013-01-01 | 2014-08-08 |
| NCT01551394 | Sepsis | Drug: Meropenem|Drug: Ampicillin + gentamicin or cefotaxime + gentamicin | PENTA Foundation|Chiesi Farmaceutici S.p.A. | Phase 3 | 2012-09-01 | 2015-02-12 |
| NCT01732250 | Gram-Negative Bacterial Infections | Drug: Colistin|Drug: Meropenem | Mical Paul|European Commission|Rabin Medical Center | Phase 4 | 2013-03-01 | 2016-12-17 |
| NCT00534287 | Severe Sepsis|Septic Shock | Drug: meropenem|Drug: meropenem, moxifloxacin | Kompetenznetz Sepsis|AstraZeneca|Bayer | Phase 3 | 2007-10-01 | 2012-06-28 |
| NCT02176122 | Bloodstream Infections | Drug: Meropenem|Drug: Piperacillin-tazobactam combination product | The University of Queensland|International Society of Chemotherapy|Australian Society for Antimicrobials|Queensland Clinical Trials & Biostatistics Centre|Australasian Society for Infectious Diseases | Phase 4 | 2014-02-01 | 2016-11-15 |
| NCT01292031 | Ventilator-associated Bacterial Pneumonia | Drug: Colistin|Drug: Meropenem | Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla|European Commission | Phase 3 | 2012-05-01 | 2016-02-02 |
| NCT01289249 | Bacterial Infection | | Oslo University Hospital | | 2011-01-01 | 2014-11-05 |
| NCT02048163 | Cystic Fibrosis | | Dayton Children's Hospital | Phase 4 | 2013-12-01 | 2016-02-04 |
| NCT02687906 | Bacterial Infections | Drug: Carbavance | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)|Department of Health and Human Services | Phase 1 | 2016-07-01 | 2016-12-01 |
| NCT00579956 | Melioidosis | Drug: Meropenem|Drug: Ceftazidime | University of Oxford|Mahidol University|Wellcome Trust | | 2007-12-01 | 2008-06-03 |
| NCT00318994 | Pancreatitis | Drug: Meropenem | AstraZeneca | Phase 4 | 2002-02-01 | 2008-01-11 |
